RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) presents aggressive clinical behavior, frequent metastasis, and limited targeted therapeutic options.
• Standard chemotherapy provided no durable response in a patient with advanced TNBC, necessitating further investigation.
• Genetic profiling is crucial for understanding treatment resistance and identifying novel therapeutic targets in TNBC.

Observation:

• Next-generation sequencing identified a PIK3CA mutation (p.E545A) and subsequent treatment with everolimus and exemestane offered only transient pain control.
• The patient's disease progressed despite PIK3CA-targeted therapy, indicating alternative oncogenic drivers.
• Crucially, next-generation sequencing revealed a significant amplification of the RICTOR gene (eight copies) in the tumor.

Findings:

• RICTOR gene amplification was identified as a potential driver in the genesis and progression of this TNBC case.
• The PIK3CA mutation suggests activation of the PI3K/AKT/mTOR pathway, but RICTOR amplification indicates a parallel or dominant pathway activation.
• The aggressive nature of the disease despite initial targeted therapy highlights the complexity of TNBC molecular subtypes.

Implications:

• Targeting RICTOR or its regulators may represent a novel therapeutic strategy for TNBC patients with RICTOR amplification.
• Understanding the interplay between PIK3CA mutations and RICTOR amplification is critical for developing effective combination therapies.
• Further research into RICTOR's role in TNBC pathogenesis could lead to improved treatment outcomes and reduced cancer cell proliferation.